Abstract:Background: Complicated with the impact of aging population and urbanization, coronary heart disease (CHD) incurs more and more disease burdens in China. Salvianolate injection is a Chinese patent drug widely used for treating CHD in China. A series of studies have verified the efficacy of salvianolate injection, but the high drug cost has raised concerns. It is, therefore, important to conduct cost-consequence analysis to demonstrate whether salvianolate injection is associated with outcome improvement and cost containment. The aim of this study was to retrospectively evaluate the cost-consequence of salvianolate injection for the treatment of coronary heart disease by combining salvianolate injection with conventional treatment from a societal perspective. Methods: We retrospectively studied hospitalized patients with CHD from August 2011 to December 2015 by using electronic medical record database. Patients who received salvianolate injection combined with conventional treatment were selected as exposed group, while those who received conventional treatment alone were selected as unexposed group. Propensity score matching (PSM) analysis was used to balance the characteristics of patients. After PSM, we evaluated hospital stay, total nitrates dosage, total medical costs, and subcategories costs. Patients with chronic ischemic heart disease were analyzed as a highly selected subcohort. Results: For the overall group, hospital stay was significantly decreased by 2.9 days (P < 0.05) and total nitrates dosage was significantly decreased by 172.4 mg (P < 0.05) in exposed group; cost savings of pharmacy cost, examination cost, laboratory cost, operation cost and treatment was observed as significant (at P < 0.05); and the additional expenditure of Chinese patent drug (1174.9 CNY) was less than the saving of total medical costs (2636.4 CNY). For chronic ischemic heart disease subcohort, compared with unexposed group, significant decreases were also found in hospital stay and total nitrates dosage (P < 0.05); cost savings were significant (P < 0.05) for exposed group in terms of total medical costs (4339.5 CNY) and subcategories costs (including pharmacy cost, examination cost, operation cost and treatment cost); and the additional expenditure of Chinese patent drug (1189.3 CNY) was less than the saving of total medical costs. Conclusion: Compared with conventional treatment for the treatment of CHD, combination of salvianolate injection and conventional treatment was associated with a reduction in hospital stay and total nitrates dosage. The acquisition cost of Chinese patent drug (including salvianolate injection) was offset by a higher reduction in total medical costs, especially for chronic ischemic heart disease.

Efficacy and Economic Evaluation of Creatine Phosphate Sodium Injection in Myocardial Protection

Clinical Study of the Protective Effect of Exogenous Creatine Phosphate on Ischemic Myocardium During Open Heart Surgery

Efficacy of sodium creatine phosphate in pediatric viral myocarditis and cellular immune functions

Clinical observations of creatine phosphate cardioplegia on myocardial protection

Creatine phosphate protects the myocardium of acute coronary syndrome patients after percutaneous coronary intervention

The Protective Effect of Aminophylline on Myocardium During Cardiopulmonary Bypass

[Myocardial Protective Effect of Acetylcholine Against Ischemia/reperfusion Injury and Its Underlying Mechanism].

Clinical Effect Analysis of Different Doses of Creatine Phosphate Sodium Combined with Immunoglobulin in the Treatment of Pediatric Viral Myocarditis

High-Energy Phosphates and Ischemic Heart Disease: From Bench to Bedside

Clinical applications of phosphocreatine and related mechanisms

Effects of acute creatine supplementation on cardiac and vascular responses in older men; a randomized controlled trial

Effects of Priming Without Plasma During Cardiopulmonary Bypass on Postoperative Recovery and Coagulation Functions of Cyanotic Congenital Heart Diseases in Children

Neuroprotection of Creatine Supplementation in Neonatal Rats with Transient Cerebral Hypoxia-Ischemia

Cost-consequence Analysis of Salvianolate Injection for the Treatment of Coronary Heart Disease

Therapeutic Application of Chick Early Amniotic Fluid: Effective Rescue of Acute Myocardial Ischemic Injury by Intravenous Administration.

International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine

Beyond sports: Efficacy and safety of creatine supplementation in pathological or paraphysiological conditions of brain and muscle

Myocardial Protection of L-carnitine in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

Effects of Long-Term Supplementing Creatine on the Endogenous Creatine Synthesis in Rats

Synergistic effect on cardiac energetics by targeting the creatine kinase system: in vivo application of high-resolution 31P-CMRS in the mouse

Effects of shenmai injection on myocardial protection in patients undergoing heart valve replacement surgery